[go: up one dir, main page]

Zhu et al., 2020 - Google Patents

Integrating intact mass analysis and middle-down mass spectrometry approaches to effectively characterize trastuzumab and adalimumab structural heterogeneity

Zhu et al., 2020

Document ID
6099049913516312845
Author
Zhu W
Li M
Zhang J
Publication year
Publication venue
Journal of Proteome Research

External Links

Snippet

Comprehensive characterization of therapeutic monoclonal antibody (mAb) structures is critical for drug development but remains challenging due to the inherent structural heterogeneity. In this study, an integrated strategy has been developed to characterize …
Continue reading at pubs.acs.org (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G01N30/8665—Signal analysis for calibrating the measuring apparatus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Similar Documents

Publication Publication Date Title
Zhu et al. Integrating intact mass analysis and middle-down mass spectrometry approaches to effectively characterize trastuzumab and adalimumab structural heterogeneity
Yan et al. Ultrasensitive characterization of charge heterogeneity of therapeutic monoclonal antibodies using strong cation exchange chromatography coupled to native mass spectrometry
Beck et al. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry
D’Atri et al. Hydrophilic interaction chromatography hyphenated with mass spectrometry: a powerful analytical tool for the comparison of originator and biosimilar therapeutic monoclonal antibodies at the middle-up level of analysis
Wei et al. Native hydrophobic interaction chromatography hyphenated to mass spectrometry for characterization of monoclonal antibody minor variants
Muneeruddin et al. Characterization of intact protein conjugates and biopharmaceuticals using ion-exchange chromatography with online detection by native electrospray ionization mass spectrometry and top-down tandem mass spectrometry
Fornelli et al. Middle-down analysis of monoclonal antibodies with electron transfer dissociation orbitrap fourier transform mass spectrometry
Beck et al. Characterization of therapeutic antibodies and related products
Fekete et al. Chromatographic, electrophoretic, and mass spectrometric methods for the analytical characterization of protein biopharmaceuticals
Gahoual et al. Detailed characterization of monoclonal antibody receptor interaction using affinity liquid chromatography hyphenated to native mass spectrometry
Beck et al. Cutting‐edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies
Jakes et al. Tracking the behavior of monoclonal antibody product quality attributes using a multi-attribute method workflow
Yan et al. Coupling mixed-mode size exclusion chromatography with native mass spectrometry for sensitive detection and quantitation of homodimer impurities in bispecific IgG
Huang et al. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS
Lodge et al. Top-down characterization of an intact monoclonal antibody using activated ion electron transfer dissociation
Zhang et al. Identification and characterization of buried unpaired cysteines in a recombinant monoclonal IgG1 antibody
Gahoual et al. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry
Nicolardi et al. Structural analysis of an intact monoclonal antibody by online electrochemical reduction of disulfide bonds and Fourier transform ion cyclotron resonance mass spectrometry
Pristatsky et al. Evidence for trisulfide bonds in a recombinant variant of a human IgG2 monoclonal antibody
Riggs et al. Sequence and solution effects on the prevalence of d-isomers produced by deamidation
Atmanene et al. Extending mass spectrometry contribution to therapeutic monoclonal antibody lead optimization: characterization of immune complexes using noncovalent ESI-MS
Camperi et al. Fast and automated characterization of monoclonal antibody minor variants from cell cultures by combined protein-A and multidimensional LC/MS methodologies
Neill et al. Characterization of recombinant monoclonal antibody charge variants using OFFGEL fractionation, weak anion exchange chromatography, and mass spectrometry
Evans et al. ID–MAM: a validated identity and multi-attribute monitoring method for commercial release and stability testing of a bispecific antibody
Haberger et al. Multiattribute monitoring of antibody charge variants by cation-exchange chromatography coupled to native mass spectrometry